Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 16;9(6):516-521.
doi: 10.1089/trgh.2022.0087. eCollection 2024 Dec.

Exogenous Hormone Use Among Transfeminine Individuals in Chiang Mai, Thailand

Malvina N Skorska  1 , Pongpun Saokhieo  2 , Lindsey T Thurston  3 , Lindsay A Coome  3 , Oranitcha Kaewthip  2 , Suwat Chariyalertsak  4 , Doug P VanderLaan  1   3
Affiliations

Exogenous Hormone Use Among Transfeminine Individuals in Chiang Mai, Thailand

Malvina N Skorska et al. Transgend Health. .

Abstract

Purpose: This study describes Thai transfeminine individuals' exogenous hormone use.

Methods: During the period May-July 2017, a survey was conducted among Thai transfeminine adults (N=181) who reported their exogenous hormone use, age at onset of use, brands used, where they obtained hormones, and discontinuation of use.

Results: Most participants (86.74%) used exogenous hormones. The mean (standard deviation) age of onset of use was 16.59 (3.79) years. A range of 1-15 brands with varying chemical composition were used. Hormones were typically procured from pharmacies (91.39%) and seldom physician prescribed (8.61%). Discontinuing use for 6 or more months was common (59.62%).

Conclusions: Gender-affirming health care beginning in adolescence for Thai transfeminine individuals is needed.

Keywords: Thailand; gender-affirming health care; hormone use; transgender.

PubMed Disclaimer

References

    1. Rosenthal SM. Challenges in the care of transgender and gender-diverse youth: An endocrinologist's view. Nat Rev Endocrinol 2021;17(10):581–591; doi: 10.1038/s41574-021-00535-9 - DOI - PubMed
    1. Foster Skewis L, Bretherton I, Leemaqz SY, et al. . Short-term effects of gender-affirming hormone therapy on dysphoria and quality of life in transgender individuals: A prospective controlled study. Front Endocrinol 2021;12:717766; doi: 10.3389/fendo.2021.717766 - DOI - PMC - PubMed
    1. Rowniak S, Bolt L, Sharifi C. Effect of cross-sex hormones on the quality of life, depression and anxiety of transgender individuals: A quantitative systematic review. JBI Database Syst Re Implement Rep 2019;17(9):1826–1854; doi: 10.11124/JBISRIR-2017-003869 - DOI - PubMed
    1. Reisner SL, Poteat T, Keatley J, et al. . Global health burden and needs of transgender populations: A review. Lancet 2016;388(10042):412–436; doi: 10.1016/S0140-6736(16)00684-X - DOI - PMC - PubMed
    1. Winter S, Diamond M, Green J, et al. . Transgender people: Health at the margins of society. Lancet 2016;388(10042):390–400; doi: 10.1016/S0140-6736(16)00683-8 - DOI - PubMed